US Imaging of Tumor Angiogenesis with Microbubbles Targeted to Vascular Endothelial Growth Factor Receptor Type 2 in Mice1

Department of Radiology and Bio-X Program, Stanford University School of Medicine, James H. Clark Center, 318 Campus Dr, East Wing, 1st Floor, Stanford, CA 94305-5427, USA.
Radiology (Impact Factor: 6.87). 02/2008; 246(2):508-18. DOI: 10.1148/radiol.2462070536
Source: PubMed


To prospectively evaluate contrast material-enhanced ultrasonography (US) with microbubbles targeted to vascular endothelial growth factor receptor type 2 (VEGFR2) for imaging tumor angiogenesis in two murine tumor models.
Animal protocols were approved by the Institutional Administrative Panel on Laboratory Animal Care. A US contrast agent, consisting of encapsulated gaseous microbubbles, was developed specifically to bind to VEGFR2 (by using anti-VEGFR2 antibodies and biotin-streptavidin interaction) which is up-regulated on endothelial cells of tumor blood vessels. VEGFR2-targeted microbubbles (MB(V)), control microbubbles (MB(C)), and nonlabeled microbubbles (MB(N)) were tested for binding specificity on cells expressing VEGFR2 (mouse angiosarcoma SVR cells) and control cells (mouse skeletal myoblast C2C12 cells). Expression of mouse VEGFR2 in culture cells was tested with immunocytochemical and Western blot analysis. Contrast-enhanced US imaging with MB(V) and MB(C) was performed in 28 tumor-bearing nude mice (mouse angiosarcoma, n = 18; rat malignant glioma, n = 10). Differences were calculated by using analysis of variance.
In cell culture, adherence of MB(V) on SVR cells (2.1 microbubbles per SVR cell) was significantly higher than adherence of control microbubbles (0.01-0.10 microbubble per SVR cell; P < .001) and significantly more MB(V) attached to SVR cells than to C2C12 cells (0.15 microbubble per C2C12 cell; P < .001). In vivo, contrast-enhanced US imaging showed significantly higher average video intensity when using MB(V) compared with MB(C) for angiosarcoma and malignant glioma tumors (P < .001). Results of immunohistochemical analysis confirmed VEGFR2 expression on vascular endothelial cells of both tumor types.
US imaging with contrast microbubbles targeted to VEGFR2 allows noninvasive visualization of VEGFR2 expression in tumor vessels in mice.

17 Reads
  • Source
    • "In ultrasound active targeting contrast imaging, antibodies, peptides, or other molecules are attached to microbubble shell. Some examples include lipid shell microbubbles attached anti-OCAM-1 monocolonal antibody for imaging acute cardiac allograft transplant rejection in rats, microbubbles targeted to vascular endothelial growth factor receptor type 2 (VEGFR2) for imaging tumor angiogenesis in murine tumor models and microbubbles with RGD peptide for thrombosis and angiogenesis targeting [46]–[48]. Also, feasibility of using recombinant human adenoviral vectors to detect nodal metastases of prostate cancer was demonstrated with adenovirus-mediated gene expression PET imaging [49] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lymphatic vessels are a part of the circulatory system in vertebrates that maintain tissue fluid homeostasis and drain excess fluid and large cells that cannot easily find their way back into venous system. Due to the lack of noninvasive monitoring tools, lymphatic vessels are known as forgotten circulation. However, the lymphatic system plays an important role in diseases such as cancer and inflammatory conditions. In this paper, we start to briefly review the current existing methods for imaging lymphatic vessels, mostly involving dye/targeting cell injection. We then show the capability of optical coherence tomography (OCT) for label-free noninvasive in vivo imaging of lymph vessels and nodes. One of the advantages of using OCT over other imaging modalities is its ability to assess label-free blood flow perfusion that can be simultaneously observed along with lymphatic vessels for imaging the microcirculatory system within tissue beds. Imaging the microcirculatory system including blood and lymphatic vessels can be utilized for imaging and better understanding pathologic mechanisms and the treatment technique development in some critical diseases such as inflammation, malignant cancer angiogenesis, and metastasis.
    IEEE Journal of Selected Topics in Quantum Electronics 03/2014; 20(2):6800510-6800510. DOI:10.1109/JSTQE.2013.2278073 · 2.83 Impact Factor
  • Source
    • "The development of gas-filled blood-pool microbubble contrast agents has significantly enhanced clinical and pre-clinical research applications with particular regard to the in vivo characterization of tissue microcirculation in a semi-quantitative and quantitative manner [63]. Novel targeted microbubble contrast agents available for research purposes open the door for a molecular evaluation of tissues, e.g. by selectively binding to vascular endothelial growth factor receptor (VEGFR-2) [64-68] and a possible theranostics application linked to high intensity focused ultrasound (HIFU) which may be used in recurrent prostate cancer [69] and the microbubble-assisted delivery of drugs and genes [70]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Innovative strategies in cancer radiotherapy are stimulated by the growing knowledge on cellular and molecular tumor biology, tumor pathophysiology, and tumor microenvironment. In terms of tumor diagnostics and therapy monitoring, the reliable delineation of tumor boundaries and the assessment of tumor heterogeneity are increasingly complemented by the non-invasive characterization of functional and molecular processes, moving preclinical and clinical imaging from solely assessing tumor morphology towards the visualization of physiological and pathophysiological processes. Functional and molecular imaging techniques allow for the non-invasive characterization of tissues in vivo, using different modalities, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET) and optical imaging (OI). With novel therapeutic concepts combining optimized radiotherapy with molecularly targeted agents focusing on tumor cell proliferation, angiogenesis, and cell death, the non-invasive assessment of tumor microcirculation and tissue water diffusion, together with strategies for imaging the mechanisms of cellular injury and repair is of particular interest. Characterizing the tumor microenvironment prior to and in response to irradiation will help to optimize the outcome of radiotherapy. These novel concepts of personalized multi-modal cancer therapy require careful pre-treatment stratification as well as a timely and efficient therapy monitoring to maximize patient benefit on an individual basis. Functional and molecular imaging techniques are key in this regard to open novel opportunities for exploring and understanding the underlying mechanisms with the perspective to optimize therapeutic concepts and translate them into a personalized form of radiotherapy in the near future.
    Radiation Oncology 01/2014; 9(1):3. DOI:10.1186/1748-717X-9-3 · 2.55 Impact Factor
  • Source
    • "It has been shown that microbubbles carrying cyclic arginine-glycine aspartic acid peptide78 and knottin peptides79 were feasible for ingtarget integrin αvβ3 in tumor models. Microbubble targeting of the angiogenic marker VEGFR-2 has been targeted by microbubble with anti-VEGFR-2 antibody80 and a single-chain VEGF construct.81 A more recent concept is multitargeting, which is the targeting against more than one molecular marker with microbubbles carrying two or three ligands, and which has improved visualization of the tumor vasculature.82 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Targeted therapy is becoming an increasingly important component in the treatment of cancer. How to accurately monitor targeted therapy has been crucial in clinical practice. The traditional approach to monitor treatment through imaging has relied on assessing the change of tumor size by refined World Health Organization criteria, or more recently, by the Response Evaluation Criteria in Solid Tumors. However, these criteria, which are based on the change of tumor size, show some limitations for evaluating targeted therapy. Currently, genetic alterations are identified with prognostic as well as predictive potential concerning the use of molecularly targeted drugs. Conversely, considering the limitations of invasiveness and the issue of expression heterogeneity, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively, and has been a particularly attractive tool for monitoring treatment in clinical cancer practice. This review focuses on the applications of different kinds of molecular imaging including positron emission tomography-, magnetic resonance imaging-, ultrasonography-, and computed tomography-based imaging strategies on monitoring targeted therapy. In addition, the key challenges of molecular imaging are addressed to successfully translate these promising techniques in the future.
    International Journal of Nanomedicine 09/2013; 8:3703-3713. DOI:10.2147/IJN.S51264 · 4.38 Impact Factor
Show more

Preview (3 Sources)

17 Reads
Available from